BioXcel Therapeutics Inc
BTAI2.990USD
-0.020-0.66%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
19.79MMarket Cap
LossP/E TTM
More Details of BioXcel Therapeutics Inc Company
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Company Info
Ticker SymbolBTAI
Company nameBioXcel Therapeutics Inc
IPO dateMar 08, 2018
CEODr. Vimal Mehta, Ph.D.
Number of employees37
Security typeOrdinary Share
Fiscal year-endMar 08
Address555 Long Wharf Dr
CityNEW HAVEN
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code06511-6107
Phone12036438060
Websitehttps://www.bioxceltherapeutics.com/
Ticker SymbolBTAI
IPO dateMar 08, 2018
CEODr. Vimal Mehta, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. David J. Mack
Mr. David J. Mack
Independent Director
Independent Director
20.32K
+9.09%
Dr. Vimal Mehta, Ph.D.
Dr. Vimal Mehta, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
20.19K
+1.93%
Dr. Michal Votruba, M.D., Ph.D.
Dr. Michal Votruba, M.D., Ph.D.
Independent Director
Independent Director
11.52K
--
Dr. Peter Mueller, Ph.D.
Dr. Peter Mueller, Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
7.49K
-42.90%
Mr. Javier Rodriguez
Mr. Javier Rodriguez
Senior Vice President, Chief Legal Officer, Corporate Secretary
Senior Vice President, Chief Legal Officer, Corporate Secretary
6.73K
+1.02%
Mr. Richard I. Steinhart
Mr. Richard I. Steinhart
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
6.51K
+1.06%
Mr. Erik Kopp
Mr. Erik Kopp
Investor Relations
Investor Relations
--
--
DR. Frank D. Yocca ,Ph.D.
DR. Frank D. Yocca ,Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Dr. Rajiv Patni, M.D.
Dr. Rajiv Patni, M.D.
Independent Director
Independent Director
--
--
Ms. June Bray
Ms. June Bray
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David J. Mack
Mr. David J. Mack
Independent Director
Independent Director
20.32K
+9.09%
Dr. Vimal Mehta, Ph.D.
Dr. Vimal Mehta, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
20.19K
+1.93%
Dr. Michal Votruba, M.D., Ph.D.
Dr. Michal Votruba, M.D., Ph.D.
Independent Director
Independent Director
11.52K
--
Dr. Peter Mueller, Ph.D.
Dr. Peter Mueller, Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
7.49K
-42.90%
Mr. Javier Rodriguez
Mr. Javier Rodriguez
Senior Vice President, Chief Legal Officer, Corporate Secretary
Senior Vice President, Chief Legal Officer, Corporate Secretary
6.73K
+1.02%
Mr. Richard I. Steinhart
Mr. Richard I. Steinhart
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
6.51K
+1.06%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Aug 17
Updated: Sun, Aug 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bioxcel Corp
2.44%
Armistice Capital LLC
1.47%
Oaktree Capital Management, L.P.
1.45%
Murchinson Ltd.
0.41%
UBS Financial Services, Inc.
0.20%
Other
94.03%
Shareholders
Shareholders
Proportion
Bioxcel Corp
2.44%
Armistice Capital LLC
1.47%
Oaktree Capital Management, L.P.
1.45%
Murchinson Ltd.
0.41%
UBS Financial Services, Inc.
0.20%
Other
94.03%
Shareholder Types
Shareholders
Proportion
Corporation
2.44%
Investment Advisor/Hedge Fund
2.00%
Hedge Fund
1.53%
Investment Advisor
0.72%
Individual Investor
0.42%
Research Firm
0.24%
Venture Capital
0.12%
Other
92.53%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
225
1.20M
19.87%
-196.86K
2025Q1
248
1.19M
19.87%
-219.94K
2024Q4
260
1.00M
33.25%
-269.93K
2024Q3
269
724.21K
25.25%
-802.39K
2024Q2
282
1.14M
44.29%
-598.60K
2024Q1
282
1.17M
59.63%
-354.60K
2023Q4
282
1.17M
63.22%
-360.50K
2023Q3
290
1.23M
67.44%
-639.74K
2023Q2
289
1.71M
93.56%
-204.68K
2023Q1
297
1.69M
93.06%
-56.17K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bioxcel Corp
480.34K
7.93%
-53.83K
-10.08%
Jun 06, 2024
Armistice Capital LLC
288.13K
4.76%
-24.20K
-7.75%
Mar 31, 2025
Murchinson Ltd.
136.08K
2.25%
+136.08K
--
Mar 31, 2025
UBS Financial Services, Inc.
101.78K
1.68%
+21.97K
+27.53%
Mar 31, 2025
Geode Capital Management, L.L.C.
22.06K
0.36%
+2.56K
+13.15%
Mar 31, 2025
Mack (David J)
16.93K
0.28%
+1.69K
+11.11%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 06, 2025
Merger
16→1
Feb 06, 2025
Merger
16→1
Feb 06, 2025
Merger
16→1
Feb 06, 2025
Merger
16→1
Date
Type
Ratio
Feb 06, 2025
Merger
16→1
Feb 06, 2025
Merger
16→1
Feb 06, 2025
Merger
16→1
Feb 06, 2025
Merger
16→1
